| 534 | 0 | 55 |
| 下载次数 | 被引频次 | 阅读次数 |
基于“肾-心-脉络”视角探讨病态窦房结综合征的病机与治疗，认为其以肾精匮乏、元气不生为起病根源，气陷生寒、心阳怫郁为发病关键环节，津血失化、脉络凝涩为导致病程迁延的机制，内蕴痰瘀、痹结心脉为促进病情加重的因素。据此提出以滋肾生元、养心复脉为核心治法，益气举陷、理郁宣阳以遏制病势，通过温补津血、荣络和脉改善预后，结合豁痰宣痹、祛瘀开结减轻病变等具体防治策略，为病态窦房结综合征的临床治疗提供参考。
Abstract：From the perspective of "kidney-heart-meridians", this paper explores the pathogenesis and treatment strategies for sick sinus syndrome(SSS). The author proposes that the root cause lies in kidney essence deficiency and failure of source qi generation. The key pathogenic mechanisms include qi sinking with cold generation and constrained heart yang. The chronic progression is attributed to impaired transformation of body fluids and blood, leading to stagnation and obstruction of the meridians. Phlegm retention and blood stasis obstructing the heart meridians are considered major factors in disease aggravation. Accordingly, the core treatment principles are to nourish the kidneys and restore source qi, tonify the heart and regulate the meridians. Supplementing qi, lifting sinking, soothing constraint, and promoting yang are employed to halt disease progression, while warming and enriching body fluids and blood aim to harmonize and unblock the meridians to improve prognosis. Strategies such as resolving phlegm, relieving obstruction, activating blood, and dispersing nodules are applied to prevent deterioration. This provides a reference framework for the clinical management of SSS.
[1]TAKASE B, IKEDA T, SHIMIZU W, et al. JCS/JHRS2022 guideline on diagnosis and risk assessment of arrhythmia[J]. Circ J, 2024,88(9):1509-1595.
[2]KHANNA S, SREEDHARAN R, TROMBETTA C, et al.Sick sinus syndrome:sinus node dysfunction in the elderly[J]. Anesthesiology,2020,132(2):377-378.
[3]HAMEED I, NUSRAT K, FARHAN SH, et al. Understanding disparities in cardiovascular death rates among older adults with sick sinus syndrome in the US[J]. Ann Med Surg(Lond),2024,86(10):5973-5979.
[4]国家心血管病中心，中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2023概要[J].中国循环杂志，2024,39(7):625-660.
[5]?INIER G, HASEEB S, BAZOUKIS G, et al. Evaluation and management of asymptomatic bradyarrhythmias[J].Curr Cardiol Rev,2021,17(1):60-67.
[6]MANOJ P, KIM JA, KIM S, et al. Sinus node dysfunction:current understanding and future directions[J]. Am J Physiol Heart Circ Physiol,2023,324(3):H259-H278.
[7]ZHAO F, XU K, ZHOU Z, et al. Morphometric CT angiographic study of the SSS and its adjacent structures:a comparative analysis between elderly and nonelderly individuals of a Han Chinese population[J]. Heliyon,2023,10(1):e23609.
[8]ORJI R, MARKSON F, ILELABOYE A, et al. Pulmonary hypertension is associated with worse outcomes in patients hospitalized for sick sinus syndrome[J]. J Innov Card Rhythm Manag,2023,14(10):5622-5628.
[9]SATHNUR N, EBIN E, BENDITT DG. Sinus node dysfunction[J]. Cardiol Clin,2023,41(3):349-367.
[10]国家心血管病中心.中国心血管健康与疾病报告2022[M].北京：中国协和医科大学出版社，2023:141-142.
[11]成之卉，周淑娴.希浦系统起搏对心功能影响的研究进展[J].中山大学学报（医学科学版），2024,45(1):1-6.
[12]MESIRCA P, FEDOROV VV, HUND TJ, et al. Pharmacologic approach to sinoatrial node dysfunction[J]. Annu Rev Pharmacol Toxicol,2021,61:757-778. doi:10.1146/annurev-pharmtox-031120-115815.
[13]卫靖靖，于瑞，郝鹏乐，等.基于隐结构模型结合关联规则分析病态窦房结综合征的方药规律[J].中国中药杂志，2023,48(22):6225-6233.
[14]CHANG X, LI Y, LIU J, et al. β-tubulin contributes to tongyang huoxue decoction-induced protection against hypoxia/reoxygenation-induced injury of sinoatrial node cells through sirt1-mediated regulation of mitochondrial quality surveillance[J]. Phytomedicine,2023,108(1):154502.
[15]CHEN M, WU Q. Roles and mechanisms of natural drugs on sinus node dysfunction[J]. Biomed Pharmacother,2023,164(8):114777.
[16]LITVI?UKOVáM, TALAVERA-LóPEZ C, MAATZ H,et al. Cells of the adult human heart[J]. Nature,2020,588(7838):466-472.
[17]CHEN L, HUA K, ZHANG N, et al. Multifaceted spatial and functional zonation of cardiac cells in adult human heart[J]. Circulation,2022,145(4):315-318.
[18]THOROLFSDOTTIR RB, SVEINBJORNSSON G,AEGISDOTTIR HM, et al. Genetic insight into sick sinus syndrome[J]. Eur Heart J,2021,42(20):1959-1971.
[19]DING Y, LANG D, YAN J, et al. A phenotype-based forward genetic screen identifies dnajb6 as a sick sinus syndrome gene[J]. Elife,2022,18(11):e77327.
[20]VAN DER MAAREL LE, POSTMA AV, CHRISTOFFELS VM. Genetics of sinoatrial node function and heart rate disorders[J]. Dis Model Mech,2023,16(5):dmm050101.
[21]YU Z, TANG PL, WANG J, et al. Mutations in hnrnpa1cause congenital heart defects[J]. JCI Insight,2018,3(2):e98555.
[22]AI-OTHMAN S, BOYETT MR, MORRIS GM, et al.Symptomatic bradyarrhythmias in the athlete-underlying mechanisms and treatments[J]. Heart Rhythm,2024,21(8):1415-1427.
[23]WU Q, CHEN Y, ZHOU Y, et al. Reliability, validity,and sensitivity of short-form 36 health survey(SF-36)in patients with sick sinus syndrome[J]. Medicine(Baltimore),2023,102(24):e33979.
[24]JARIWALA P, GUDE D, KULKARNI GP, et al. Sinoatrial nodal artery occlusion causing acute sinus node dysfunction after percutaneous coronary intervention:case report and systematic review[J]. Pacing Clin Electrophysiol,2024,47(8):1038-1048.
[25]陈爱月，郑黎晖.心脏神经消融术治疗功能性窦房结功能障碍的研究进展[J].中国循环杂志，2024,39(11):1140-1144.
[26]MEYER KM, MALHOTRA N, KWAK JS, et al. Relevance of KCNJ5 in pathologies of heart disease[J]. Int J Mol Sci, 2023,24(13):10849.
[27]张静华，李平，郭华，等.心率变异性在病态窦房结综合征患者中特征及诊断价值[J].中华实用诊断与治疗杂志，2023,37(8):757-761.
[28]封雪，田甜，肖芳，等.斑点追踪技术评估病态窦房结综合征伴阵发性心房颤动患者左室功能[J].临床超声医学杂志，2022,24(3):171-175.
[29]张文杰，张印明，李军，等.中医药治疗病态窦房结综合征起搏器植入术后并发症研究概述[J].山东中医药大学学报，2023,47(6):795-799.
[30]CHURYLA A, MCCARTHY PM, KRUSE J, et al. Concomitant ablation of atrial fibrillation:new pacemakers and early rhythm recovery[J]. J Thorac Cardiovasc Surg, 2024,168(6):1677-1685.
[31]DI MAMBRO C, CALVIERI C, SILVETTI MS, et al.Bradyarrhythmias in repaired atrioventricular septal defects:single-center experience based on 34 years of follow-up of 522 patients[J]. Pediatr Cardiol,2018,39(8):1590-1597.
基本信息:
DOI：10.13288/j.11-2166/r.2025.14.008
中图分类号:R259
引用信息:
[1]蔡泳源,严诏琦,刘志明,等.从“肾-心-脉络”视角探讨病态窦房结综合征的病机与治疗[J].中医杂志,2025,66(14):1450-1455.DOI:10.13288/j.11-2166/r.2025.14.008.
基金信息:
国家中医药管理局国医大师传承工作室项目; 中国中医科学院学部委员学术传承与传播专项（CI2022E012XB）; 中央高水平中医医院临床科研业务费资助项目（HLCMHPP2023053）; 北京中医药薪火传承“新3+3”工程（2023-SZ-F-06,2023-SZ-G-02）